Anthony Coyle

USPTO Granted Patents = 20 (Patent Applications = 27)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 5.8

ph-index = 6

Forward Citations = 193(Granted Patents)

Location History:

Washington, DC (US) (2009 - 2012)
Washington,, DC (US) (2012)
Boston, MA (US) (2003 - 2024)

Company Filing History:

Millennium Pharmaceuticals Limited

The Brigham and Women's Hospital, Inc.

The Feinstein Institute for Medical Research

patents

8. 1 out of 36

Flagship Pioneering Innovations Vi, LLC

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448439 - Interferon beta antibodies and uses thereof (2025-10-21),

2. 12110324 - Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) (2024-10-08),

3. 11858986 - Interferon beta antibodies and uses thereof (2024-01-02),

4. 11555062 - Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer (2023-01-17),

5. 11104720 - Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit (2021-08-31),

6. 10829553 - Interferon beta antibodies and uses thereof (2020-11-10),

7. 10301390 - Anti-IFNAR1 antibodies with reduced Fc ligand affinity (2019-05-28),

8. 10000553 - CD40L-specific TN3-derived scaffolds and methods of use thereof (2018-06-19),

9. 9988459 - Anti-IFNAR1 antibodies with reduced Fc ligand affinity (2018-06-05),

10. 9896505 - Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease (2018-02-20),

11. 9193789 - Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease (2015-11-24),

12. 8883992 - Humanized anti-CD19 antibodies (2014-11-11),

13. 8323653 - Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease (2012-12-04),

14. 8153131 - High affinity antibodies against HMGB1 and methods of use thereof (2012-04-10),

15. 8129130 - High affinity antibodies against HMGB1 and methods of use thereof (2012-03-06),

Title: Anthony Coyle: Innovator in Therapeutic Antibody Development

Introduction: Anthony Coyle is an accomplished inventor based in Boston, MA, recognized for his significant contributions to the field of therapeutic antibodies. With a remarkable portfolio of 18 patents, his work focuses particularly on innovations related to autoimmune diseases and diagnostic methods.

Latest Patents: Among Anthony's latest patents are groundbreaking inventions that include "Interferon beta antibodies and uses thereof." This invention pertains to antibodies that specifically bind to interferon beta (IFNβ), which have therapeutic and diagnostic applications. Another notable patent is "Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer." This invention presents engineered scaffolds based on the Tenascin-3 FnIII domain that bind specifically to CD40L, aimed at treating systemic lupus erythematosus (SLE) and other autoimmune conditions.

Career Highlights: Throughout his career, Anthony has worked with leading companies in the biotechnology industry. Notably, he has been associated with MedImmune Limited and Millennium Pharmaceuticals Limited, where he contributed to the development of innovative treatments and therapies.

Collaborations: In addition to his individual achievements, Anthony has collaborated with esteemed colleagues such as Peter Kiener and Herren Wu, contributing to advancements in therapeutic solutions and immunology research.

Conclusion: Anthony Coyle's innovative spirit and dedication to the field of therapeutic antibody development have significantly impacted medical research and treatment options. His patents serve as a testament to his expertise and commitment to alleviating autoimmune diseases and enhancing diagnostic capabilities.

This text is generated by artificial intelligence and may not be accurate.